Jinling Pharmaceutical Company Limited

000919

CNE0000010W5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-06 EDT			5-day change	1st Jan Change
6.53 ^CNY	+1.71%		-5.91%	-17.03%

05-24	Jinling Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2023, Payable on 31 May 2024	CI
05-22	Jinling Pharmaceutical Company Limited Approves Cash Dividend for the Year 2023	CI

Jinling Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2023

April 29, 2024

Jinling Pharmaceutical Company Limited proposed final cash dividend of CNY 1.0000000 per ten shares (tax included) for the year 2023.

Latest news about Jinling Pharmaceutical Company Limited

Jinling Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2023, Payable on 31 May 2024	05-24	CI
Jinling Pharmaceutical Company Limited Approves Cash Dividend for the Year 2023	05-21	CI
Jinling Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2023	04-29	CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Hefei Jinling Tianyi Smart Elderly Care Services Co., Ltd. announced that it expects to receive CNY 600 million in funding from Jinling Pharmaceutical Company Limited	04-25	CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Jinling Pharmaceutical Company Limited announced that it has received CNY 749.999998 million in funding from a group of investors	04-07	CI
Jinling Pharma in Talks to Buy Over 50% Stake in Local Hospital	01-05	MT
Jinling Pharmaceutical Company Limited agreed to acquire 43.6% stake in Nanjing Meishan Hospital Co., Ltd. from Nanjing New Industrial Investment Group Co.,Ltd. and Nanjing Zijin Investment Management Co., Ltd.	01-04	CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Jinling Pharma Selling 750 Million Yuan Shares to Fund New Projects	23-07-24	MT
Jinling Pharmaceutical Company Limited Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 14 July 2023	23-07-07	CI
Jinling Pharmaceutical Company Limited Approves Management Appointments	23-06-29	CI
Jinling Pharmaceutical Company Limited Approves Cash Dividend for the Year 2022	23-05-24	CI
Jinling Pharmaceutical Vice Chairman Resigns	23-05-15	MT
Jinling Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Jinling Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2022	23-03-23	CI
Jinling Pharmaceutical Company Limited announced that it expects to receive CNY 750 million in funding from Nanjing New Industrial Investment Group Co., Ltd and other investors	23-02-23	CI
Jinling Pharma Gets 155 Million Yuan Compensation for Office Demolition, Relocation	23-01-23	MT
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Jinling Pharmaceutical Company Limited Implements Final Profit Distribution for 2021, Payable on August 11, 2022	22-08-04	CI
Jinling Pharmaceutical Company Limited Approves Cash Dividend for the Year 2021	22-06-29	CI
Jinling Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI

Chart Jinling Pharmaceutical Company Limited

Duration

Period

Chart Jinling Pharmaceutical Company Limited

More charts

Jinling Pharmaceutical Company Limited is a China-based company principally engaged in the manufacture and sale of traditional Chinese medicines and chemical drugs. The Companyâs main products include Mailuoning injections, ferrous succinate tablets and Lentinan injection, among others. The Company is also involved in the provision of medical services and the sale of medical instrument. The Company distributes its products in domestic market, with North China as its main market.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JINLING PHARMACEUTICAL COMPANY LIMITED	-17.03%	557M
ELI LILLY AND COMPANY	+46.26%	754B
NOVO NORDISK A/S	+40.95%	630B
JOHNSON & JOHNSON	-5.93%	352B
MERCK & CO., INC.	+19.77%	331B
ABBVIE INC.	+9.45%	298B
ASTRAZENECA PLC	+18.45%	250B
NOVARTIS AG	+11.88%	217B
ROCHE HOLDING AG	-0.78%	216B
AMGEN INC.	+6.24%	164B